Welcome to our dedicated page for Immatics news (Ticker: IMTX), a resource for investors and traders seeking the latest updates and insights on Immatics stock.
Immatics N.V. develops clinical-stage cancer immunotherapies built around T-cell receptor biology, with a stated focus on precision targeting of PRAME across solid tumors. News about IMTX most often covers clinical updates for PRAME-directed cell therapies and TCR bispecifics, including anzu-cel (anzutresgene autoleucel, IMA203), IMA203CD8, IMA402 and IMA401 MAGEA4/8. Company announcements also cover presentations at oncology meetings such as ASCO, AACR and ESMO, where Immatics reports safety, dose-escalation and anti-tumor activity data across melanoma, ovarian cancer, synovial sarcoma and other PRAME-positive cancers.
Recurring updates include financial results, business updates, collaboration activity, clinical and regulatory disclosures, leadership changes, shareholder voting matters and capital-structure disclosures for the Nasdaq-listed biotechnology company.
Immatics (NASDAQ: IMTX) has agreed to a $150 million underwritten offering, selling 12,945,916 ordinary shares at $8.69 per share and pre-funded warrants for 4,315,304 ordinary shares at $8.689 per warrant. The pre-funded warrant price reflects the share price minus a $0.001 exercise price.
Gross proceeds are expected to total $150 million before underwriting discounts and expenses, with closing targeted for August 26, 2026, subject to customary conditions. Immatics granted underwriters a 30-day option to buy up to 2,589,184 additional shares at the public price, less the underwriting discount. Jefferies, Leerink Partners and Cantor are joint book-running managers, and the SEC registration statement for these securities was declared effective on April 3, 2025.
Immatics (NASDAQ: IMTX) reported second quarter 2026 results and a broad PRAME-franchise update. Cash and financial assets totaled $448.2 million as of June 30, 2026, with cash reach projected into 2028. Q2 revenue from collaborations was $10.4 million, up from $5.4 million a year earlier, while net loss narrowed to $71.2 million from $80.1 million despite higher R&D spending of $71.1 million driven mainly by the Phase 3 SUPRAME trial.
Enrollment in SUPRAME for anzu-cel (IMA203) in advanced melanoma remains on track to complete randomizations by year-end, with a protocol change to a single final PFS analysis and expanded OS power in ~450 patients. Topline PFS data are expected in H1 2027, with a planned BLA submission in 2027. Updated Phase 1b anzu-cel data in metastatic melanoma showed a 56% confirmed ORR and 16.2 months mOS, while IMA203CD8 and IMA402 continued to show clinical activity across multiple PRAME-positive solid tumors. Immatics also reported the first patient dosed in Moderna’s mRNA-4200 trial, triggering a milestone payment.
Immatics (NASDAQ: IMTX) announced three upcoming presentations from its PRAME-targeted pipeline at the ESMO Congress 2026, held October 23–27, 2026, in Madrid, Spain. The data span Phase 1/1b trials of lead PRAME cell therapies anzu-cel and IMA203CD8, and bispecific candidate IMA402 across multiple solid tumors, including advanced melanoma and gynecologic cancers. Full abstracts are scheduled for release on October 19, 2026, on the ESMO website.
Immatics (NASDAQ: IMTX) reported extended Phase 1b data for its PRAME TCR T-cell therapy anzu-cel (IMA203) in heavily pretreated metastatic melanoma at the 2026 ASCO meeting.
At the RP2D, anzu-cel showed a 56% confirmed ORR, 14.6-month mDOR, 6.1-month mPFS, 16.2-month mOS and a predictable, manageable safety profile, supporting the ongoing SUPRAME Phase 3 trial and a planned BLA submission in 1H 2027.
Immatics (NASDAQ:IMTX) reported Phase 1 data for IMA401, a MAGEA4/8 TCR bispecific, in heavily pretreated solid tumors. At the recommended Phase 2 dose, IMA401 with or without pembrolizumab showed a 29% confirmed ORR and 64% DCR in head and neck cancer, with 8.8-month mDOR.
Melanoma patients achieved 33% cORR and 67% DCR, with responses lasting over six months. Safety showed mostly low-grade CRS, lymphopenia and neutropenia, with no ICANS observed. These data support an ongoing Phase 1 IMA401/IMA402 combination cohort in sqNSCLC, with first data expected in 2027.
Immatics (NASDAQ:IMTX) reported updated Phase 1 data for its PRAME-targeting TCR T-cell therapy IMA203CD8 in gynecologic cancers and synovial sarcoma at ASCO 2026.
In clinically relevant gynecologic cohorts, ORR was 63% with 50% confirmed, including four complete responses. In synovial sarcoma, ORR was 67%, confirmed ORR 64%, with durable responses up to ~3 years. IMA203CD8 showed a manageable safety profile without treatment-related Grade 5 events, and Immatics expects to define the recommended Phase 2 dose (RP2D) in 2026 and present further data in the second half of 2026.
Immatics (NASDAQ: IMTX) reported Q1 2026 results and a broad PRAME-focused clinical pipeline update. Cash, cash equivalents and other financial assets were $521.5 million as of March 31, 2026, with cash reach projected into 2028.
Key 2026 milestones include Phase 3 SUPRAME interim/final analyses for anzu-cel in advanced melanoma, multiple PRAME cell therapy and bispecific data readouts, and progress toward a planned 2027 BLA filing and first commercial launch.
Immatics (NASDAQ: IMTX) announced four oral presentations at the 2026 ASCO Annual Meeting (May 29–June 2, 2026) featuring updated Phase 1/1b clinical data for PRAME-directed cell therapies anzucel (IMA203), IMA203CD8 (GEN2), PRAME TCR therapies in synovial sarcoma, and first-in-human IMA401 bispecific results.
Abstracts will be available on May 21, 2026 at 5:00 pm ET; sessions occur May 30–June 1 in Chicago, IL.
Immatics (NASDAQ: IMTX) reported a late-breaking AACR 2026 poster of an individual pediatric case showing deep, durable remission after treatment with a PRAME-directed TCR T-cell therapy.
A 17-year-old with metastatic PRAME-positive nephroblastoma (16 cm abdominal lesion; lung, liver, brain mets) achieved radiologic and molecular remission with response ongoing at 6 months; cytokine release syndrome was manageable and resolved.
Immatics (NASDAQ: IMTX) reported full-year 2025 results and a business update on March 5, 2026, highlighting clinical progress across its PRAME franchise and financials. Cash and other financial assets totaled $551.4 million as of December 31, 2025, with cash reach extended into 2028.
Key clinical timelines include SUPRAME Phase 3 interim and final analyses expected in 2026, BLA submission in 1H 2027, and commercial launch in 2H 2027. The company completed a $125 million public offering on December 8, 2025.